

## ENSAYOS CLÍNICOS GLÁNDULAS SALIVALES ABIERTOS A RECLUTAMIENTO ( Actualizado Junio 2020)

FUENTE de la INFORMACIÓN OBTENIDA: [Clinical Trials.gov](https://clinicaltrials.gov/); [EU Clinical Trials Register](https://european-clinical-trials-register.eu/); REEC (AEMPS)

EudraCT-Number	NCT	CODIGO_ESTUDIO	TITULO_ESTUDIO	FASE	INDICACION	ESTADO	MEDICACION	CENTROS	PROMOTOR	ESPECIALIDAD	COMENTS
<a href="#">2015-002067-41</a>	<a href="#">2628067</a>	3475-158	Ensayo clínico de evaluación de biomarcadores predictivos con pembrolizumab (MK-3475) en pacientes con tumores sólidos avanzados (KEYNOTE 158)	Fase II	<b>Tumores sólidos avanzados (Thyroid Carcinoma Salivary Gland Carcinoma)</b>	RECLUTING	<b>Pembrolizumab (i.v)</b>	H.U.Vall d' Hebron(BCN) H.U.Ramon y Cajal (Madrid) H.U.12 Octubre (Madrid)	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	Oncologia Medica	N= 1295 Single Group Assignment
<a href="#">2015-003385-84</a>	<a href="#">2568267</a>	RXDX-101-02	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid <b>Tumors</b> That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Fase II	<b>Salivary Gland Cancers &amp; Adult Solid Tumor</b> (Papillary thyroid cancer and H&N cancer)	RECLUTING	<b>Entrectinib</b>	H.U.Vall d' Hebron(BCN) H.U.Ramon y Cajal (Madrid) H.U.12 Octubre (Madrid) H.C.U.San Carlos (Madrid) Start_CIOClara Campal (Madrid) H.U.V.Victoria (Malaga) H.U.V.Rocio (Sevilla)	Hoffma-La Roche / Ignyta, Inc	Oncologia Medica	N = 300
<a href="#">2015-003582-28</a>	<a href="#">2576431</a>	LOXO-TRX-15002(NAVEGATE)	A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects With NTRK Fusion-positive <b>Tumors</b>	Phase II	Experimental: <b>Arm 5_Salivary</b> , Patients with solid salivary tumors harboring NTRK fusions	RECLUTING	<b>Larotrectinib</b> will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles. <b>BAY2757556 (Larotrectinib)</b> Other Name:LOXO-101	H.U.San Chinarro(Madrid) F.Jimenez Diaz (Madrid)	Bayer	Oncologia_Medica	N= 203 <b>12 years and older</b>